Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hi-tech pharmacal co. inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs, neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidimiology and susceptibility patterns may contribute to the empiric selection of therapy. suppression of intestinal bacteria : neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, eg, preoperative preparation of the bowel. it is given concomitantly with erythromycin enteric-coated base (see dosage and administration section) . hepatic coma (portal-systemic encephalopathy) : neomycin sulfate has been shown to be effective adjunctive therapy in hepatic com

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

vensun pharmaceuticals, inc. - nystatin (unii: bdf1o1c72e) (nystatin - unii:bdf1o1c72e) - nystatin 100000 [usp'u] in 1 g - nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by candida albicans  and other susceptible candida species. nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.  nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any of its components.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

vensun pharmaceuticals, inc. - nystatin (unii: bdf1o1c72e) (nystatin - unii:bdf1o1c72e) - nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by candida  albicans  and other susceptible candida  species. nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.  nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any  of its components.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

medical purchasing solutions, llc - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 500 mg in 5 ml - levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. levetiracetam is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. levetirecetam is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. levetiracetam injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible. levetiracetam injection is contraindicted in patients with a hypersensitivity to levetiracetam.  reactions have included anaphylaxis and angioedema. [see warnings and precautions (5.3) ]. there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including levetiracetam injection, during pregnancy. encourage women who are taking levetiraceta

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

telom-x gene co., ltd. - sulfate ion (unii: 7is9n8kpmg) (sulfate ion - unii:7is9n8kpmg), potassium cation (unii: 295o53k152) (potassium cation - unii:295o53k152), chloride ion (unii: q32zn48698) (chloride ion - unii:q32zn48698) - sulfate ion 3.6 g in 1 l - first aid to help prevent infection in minor: - cuts - scrapes - burns apply to the area which is wounded or burnt

Tanzania - engleză - Tanzania Medicinces & Medical Devices Authority

inqaba biotec east africa limited, tanzania - laboratory equipment -

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - nystatin (unii: bdf1o1c72e) (nystatin - unii:bdf1o1c72e) - nystatin 100000 [usp'u] in 1 g - nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by candida albicans  and other susceptible candida species. nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.  nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any of its components.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 100 mg in 1 ml - tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection is contraindicated: • in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection in such patients. • in patients with active intravascular clotting [see warnings and precautions (5.1)]. • in patients with hypersensitivity to tranexamic acid or any of the ingredients [see warnings and precautions (5.3)]. available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. there are 2 (0.02%) infant cases with structural abnormalities that resulted in death when

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

medical purchasing solutions, llc - rocuronium bromide (unii: i65mw4ofhz) (rocuronium - unii:wre554rfez) -  rocuronium bromide injection is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. rocuronium bromide injection is contraindicated in patients known to have hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents [see warnings and precautions (5.2)]. pregnancy category c: developmental toxicology studies have been performed with rocuronium bromide in pregnant, conscious, nonventilated rabbits and rats. inhibition of neuromuscular function was the endpoint for high-dose selection. the maximum tolerated dose served as the high dose and was administered intravenously 3 times a day to rats (0.3 mg/kg, 15%-30% of human intubation dose of 0.6-1.2 mg/kg based on the body surface unit of mg/m2) from day 6 to 17 and to rabbits (0.02 mg/kg, 25% human dose) from day 6 to 18 of pregnancy. h